natgillin/translations-raw huggingface dataset:
As a conservative measure in view of the limitations of the data, in treatment naïve patients-late responders, the treatment duration of the tritherapy is recommended to be prolonged to 32 weeks as compared to the tested 24 weeks duration of the tritherapy, for a total treatment duration of 48 weeks. 
Kao konzervativna mjera obzirom na ograničene podatke preporučuje se u bolesnika koji prethodno nisu bili liječeni, s kasnim odgovorom na liječenje, produljiti trajanje trojne terapije na 32 tjedna, u usporedbi s 24 tjedna liječenja u ispitivanjima, čime bi cjelokupno liječenje trajalo 48 tjedana.
All subjects with detectable HCV-RNA in plasma at TW 24 were discontinued from treatment. 
Svi ispitanici s mjerljivom HCV-RNK u plazmi u 24. tjednu liječenja isključeni su iz liječenja.
All patients in this treatment arm were limited to 24 weeks of therapy with Victrelis. 
Svim bolesnicima u ovoj terapijskoj skupini liječenje lijekom Victrelis bilo je ograničeno na 24 tjedna.
In clinical trials with the combination of Victrelis, peginterferon alfa-2b and ribavirin compared to peginterferon alfa-2b and ribavirin alone, the median time from the initiation of therapy to onset of haemoglobin less than 10 g/dL was similar (71 days with a range of 15-337 days, and 71 days with a range of 8-337 days, respectively). 
U kliničkim ispitivanjima u kojima se uspoređivala kombinacija lijeka Victrelis, peginterferona alfa-2b i ribavirina s primjenom samo peginterferona alfa-2b i ribavirina, medijan vremena od početka terapije do pada vrijednosti hemoglobina na manje od 10 g/dl bio je podjednak (71 dan uz raspon od 15-337 dana, odnosno 71 dan uz raspon od 8-337 dana).
Eleven subjects were missing TW 4 assessment (HCV-RNA) and were not included in the Lead-In 
Za 11 ispitanika nedostajala je procjena nakon 4. tjedna liječenja (razina HCV-RNK) i oni nisu uključeni u rezultate odgovora na uvodno liječenje.
Rilpivirine* (rilpivirine 25 mg every 24 hours + Victrelis 800 mg three times daily) 
Rilpivirin* (rilpivirin 25 mg svaka 24 sata + Victrelis 800 mg triput na dan)
The efficacy of Victrelis as a treatment for chronic hepatitis C genotype 1 infection was assessed in approximately 1,500 adult subjects who were previously untreated (SPRINT-2) or who had failed previous therapy (RESPOND-2) in Phase III clinical studies. 
Djelotvornost lijeka Victrelis u liječenju kroničnog hepatitisa C genotipa 1 ispitana je u kliničkim ispitivanjima faze III u približno 1500 odraslih ispitanika koji prethodno nisu bili liječeni (SPRINT-2) ili nisu odgovorili na prethodnu terapiju (RESPOND-2).
Some cases have also been reported in patients coinfected with hepatitis B and C viruses treated with interferon (refer to the Summary of Product Characteristics for peginterferon alfa for more information on HBV reactivation in patients coinfected with HBV and HCV treated with interferon). 
Neki slučajevi su prijavljeni i u bolesnika istodobno zaraženih virusom hepatitisa B i C liječenih interferonom (za više informacija o reaktivaciji HBV-a u bolesnika istodobno zaraženih HBV-om i HCV-om liječenih interferonom, pročitajte sažetak opisa svojstava lijeka za peginterferon alfa).
Table 1 Duration of therapy using Response-Guided Therapy (RGT) guidelines in patients without cirrhosis who are previously untreated or who have failed previous therapy to interferon and ribavirin therapy 
Response-Guided Therapy, RGT) u bolesnika bez ciroze koji prethodno nisu bili liječeni ili nisu odgovorili na prethodnu terapiju interferonom i ribavirinom
You or your partner must use an effective birth control during the time you are taking ribavirin and for 7 months after stopping treatment. 
Vi i Vaša partnerica morate koristiti djelotvornu kontracepciju tijekom liječenja ribavirinom i 7 mjeseci po njegovu završetku.
Safety and efficacy of Victrelis, in combination with peginterferon alfa and ribavirin, have not been studied in patients with decompensated cirrhosis. 
Sigurnost i djelotvornost lijeka Victrelis, u kombinaciji s peginterferonom alfa i ribavirinom, nisu ispitivane u bolesnika s dekompenziranom cirozom.
In clinical trials, the proportion of subjects who received erythropoietin for the management of anaemia was 43% (667/1,548) of subjects in the Victrelis-containing arms compared to 24% (131/547) of subjects receiving peginterferon alfa-2b and ribavirin alone. 
U kliničkim je ispitivanjima udio bolesnika koji su primili eritropoetin za liječenje anemije bio 43% (667/1548) u skupinama ispitanika koji su primali Victrelis, a 24% (131/547) u skupinama koje su primale samo peginterferon alfa-2b i ribavirin.
9/L (Grade 4 neutropenia) compared to 4% of subjects receiving only peginterferon alfa-2b and ribavirin. 
9/l neutrofila (neutropeniju stupnja 4), u usporedbi s 4% ispitanika koji su primali samo peginterferon alfa-2b i ribavirin.
Other clinical experience has not identified differences in responses between the older and younger patients (see section 5.2). 
Ostalo kliničko iskustvo nije pokazalo razlike u odgovoru na liječenje između starijih i mlađih bolesnika
• Store in a refrigerator until expiry. 
• Čuvati u hladnjaku do isteka roka valjanosti.
C-boceprevir, approximately 79% and 9% of the dose was excreted in faeces and urine, respectively, with approximately 8% and 3% of the dosed radiocarbon eliminated as boceprevir in faeces and urine. 
Nakon jednokratne peroralne doze od 800 mg C-boceprevira, oko 79% doze izluči se stolicom, a oko 9% mokraćom, dok se oko 8% primijenjenog radiougljika eliminira kao boceprevir stolicom, a oko 3% mokraćom.
The subjects were then continued on different regimens based on Treatment Week (TW) 8 response-guided therapy (Victrelis-RGT). 
Ispitanici su nakon toga nastavili liječenje različitim režimima ovisno o odgovoru u 8. tjednu liječenja prema smjernicama "liječenja prema odgovoru" (Victrelis-RGT).
The treatment discontinuation rate due to anaemia was 2% (5/249) in subjects randomized to receive ribavirin dose reduction and 2% (6/251) in subjects randomized to receive erythropoietin. 
Stopa prekida liječenja zbog anemije iznosila je 2% (5/249) u ispitanika randomiziranih za snižavanje doze ribavirina te 2% (6/251) u ispitanika randomiziranih za primanje eritropoetina.
938/non-Black and Cohort 2 /Black N=159) and stratified by HCV genotype (1a or 1b) and by HCVRNA viral load (≤ 400,000 IU/mL vs. > 400,000 IU/mL) to one of the following three treatment arms: 
Ispitanici su podijeljeni u dvije kohorte (kohorta 1 N= 938/sve rase osim crne i kohorta 2/crnci N= 159) i stratificirani prema genotipu HCV-a (1a ili 1b) i prema virusnom opterećenju HCV-RNK (≤ 400 000 IU/ml naspram > 400 000 IU/ml) te randomizirani u omjeru 1:1:1 u jednu od sljedeće tri
Table 5 presents sustained virologic response per treatment arm in previously untreated patients who were early responders and late responders and that received similar therapy up to treatment week 28. 
Tablici 5 prikazan je trajan virološki odgovor po terapijskim skupinama u bolesnika koji prethodno nisu bili liječeni s ranim ili kasnim odgovorom na liječenje koji su primali sličnu terapiju do 28. tjedna liječenja.
Lopinavir/Ritonavir* (lopinavir 400 mg / ritonavir 100 mg two times daily + Victrelis 800 mg three times daily) 
Lopinavir/ritonavir* (lopinavir 400 mg/ritonavir 100 mg dvaput na dan + Victrelis 800 mg triput na dan)
Victrelis does not inhibit or induce the other enzymes 
Victrelis ne inhibira niti inducira druge enzime citokroma CYP450.
Each capsule contains 56 mg of lactose monohydrate. 
Pomoćna tvar s poznatim učinkom Jedna kapsula sadrži 56 mg laktoze hidrata.
Mean age of subjects randomized was 49 years. 
Srednja dob randomiziranih ispitanika bila je 49 godina.
The following double amino acid substitutions conferred more than 10-fold reduced sensitivity to boceprevir: V55A+I170V, T54S+R155K, R155K+D168N, R155T+D168N and 
Sljedeće dvostruke aminokiselinske supstitucije smanjile su osjetljivost na boceprevir više od 10 puta: V55A+I170V, T54S+R155K, R155K+D168N, R155T+D168N i V36M+R155K.
‡ % (n/N) Relapse % (n/N) 
‡ % (n/N) Relaps % (n/N)
While taking the combination of Victrelis with ribavirin and peginterferon alpha, serious allergic reactions have been reported. 
Kod primjene lijeka Victrelis u kombinaciji s ribavirinom i peginterferonom alfa prijavljene su ozbiljne alergijske reakcije.
Titanium dioxide (E171) Yellow iron oxide (E172) Red iron oxide (E172) 
želatina titanijev dioksid (E171)
Not known (frequency cannot be estimated from the available data) Skin and hair: Severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung (a reaction called DRESS); serious skin reaction, including blistering or peeling of the skin (a reaction called Stevens-Johnson syndrome) 
Nepoznate (učestalost se ne može procijeniti iz dostupnih podataka) Koža i kosa: težak osip, uz koji se mogu javiti vrućica, umor, oticanje lica ili limfnih žlijezda, povećan broj eozinofila (jedne vrste bijelih krvnih stanica), učinci na jetru, bubrege ili pluća (reakcija koja se naziva DRESS); ozbiljna kožna reakcija, uključujući nastanak mjehurića ili ljuštenje kože (reakcija koja se naziva Stevens-Johnsonovim sindromom) Bubreg: oštećenje funkcije bubrega (u načelu se povlači nakon završetka liječenja)
You must use an effective birth control during the time you are taking ribavirin and for 4 months after stopping treatment. 
Morate koristiti djelotvornu kontracepciju tijekom liječenja ribavirinom i 4 mjeseca po njegovu završetku.
No dose adjustment of Victrelis or rilpivirine is recommended. 
Ne preporučuje se prilagođavati dozu lijeka Victrelis niti rilpivirina.
Sustained Virologic Response (SVR) in patients receiving similar therapy up to treatment week 28 
Trajan virološki odgovor (SVR) u bolesnika koji su primali sličnu terapiju do 28. tjedna liječenja
• antifungal medicines - ketaconazole, itraconazole, posaconazole, voriconazole 
• lijekove protiv gljivičnih infekcija - ketokonazol, itrakonazol, posakonazol, vorikonazol
• are taking bepridil, pimozide, lurasidone, oral midazolam, oral triazolam, simvastatin, lovastatin, alfuzosin, silodosin, 'ergot' type medicines (such as dihydro-ergotamine, ergonovine, ergotamine or methylergonovine), lumefantrine, halofantrine, quetiapine, or tyrosine kinase inhibitors. 
• ako uzimate bepridil, pimozid, lurasidon, oralni midazolam, oralni triazolam, simvastatin, lovastatin, alfuzozin, silodozin, lijekove iz skupine derivata ergota (kao što su dihidroergotamin, ergonovin, ergotamin ili metilergonovin), lumefantrin, halofantrin, kvetiapin ili inhibitore tirozin kinaze.
• HIV protease inhibitors - atazanavir, darunavir, lopinavir, ritonavir 
• inhibitore HIV proteaze - atazanavir, darunavir, lopinavir, ritonavir
As compared to the combination of boceprevir with peginterferon alfa-2b and ribavirin, the combination of boceprevir with peginterferon alfa-2a and ribavirin was associated with a higher rate of neutropenia (including grade 4 neutropenia) and a higher rate of infections. 
U usporedbi s primjenom boceprevira u kombinaciji s peginterferonom alfa-2b i ribavirinom, kombinacija boceprevira s peginterferonom alfa-2a i ribavirinom povezana je s većom stopom neutropenije (uključujući neutropeniju stupnja 4) i većom stopom infekcija.
Subjects were randomized in a 1:2:2 ratio and stratified based on response to their previous qualifying regimen (relapsers vs. partial responders) and by HCV subtype (1a vs. 1b) to one of the following treatment arms: 
Ispitanici su stratificirani na temelju odgovora na prethodni režim liječenja koji ih je kvalificirao za ovo ispitivanje (ispitanici s relapsom naspram ispitanika s djelomičnim odgovorom) i prema podtipu genotipa HCV-a (1a naspram 1b) te u omjeru 1:2:2 randomizirani u jednu od sljedećih terapijskih skupina:
Interferon-responsiveness (as defined by ≥ 1-log10 decline in viral load at TW 4) was predictive of SVR. 
Odgovor na interferon (definiran kao smanjenje virusnog opterećenja od ≥ 1-log10 u 4. tjednu liječenja) bio je pretkazatelj SVR.
HIV Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) 
Nenukleozidni inhibitori HIV reverzne transkriptaze (NNRTI)
The number of subjects with cirrhosis is limited (where 39 subjects were treated with Victrelis of 
Broj ispitanika s cirozom je ograničen (39 od ukupno 49 ispitanika liječeno je lijekom Victrelis).
It is possible that boceprevir is excreted in human milk. 
Moguće je da se boceprevir izlučuje u majčino mlijeko.
Discontinuation of therapy is recommended in all patients with 1) HCV-RNA levels of greater than or equal to 1,000 IU per mL at TW 8; or 2) HCV-RNA levels of greater than or equal to 100 IU per mL at TW 12; or 3) confirmed, detectable HCV-RNA levels at TW 24. 
Prekid liječenja preporučuje se svim bolesnicima koji: 1.) u 8. tjednu liječenja imaju razine HCV-RNK veće ili jednake vrijednosti od 1000 IU po ml, ili 2.) u 12. tjednu liječenja imaju razine HCV-RNK veće ili jednake vrijednosti od 100 IU po ml, ili 3.) u 24. tjednu liječenja imaju potvrđene i mjerljive
• Victrelis is always taken in combination with peginterferon alfa and ribavirin. 
• Victrelis se uvijek uzima u kombinaciji s peginterferonom alfa i ribavirinom.
The addition of boceprevir to peginterferon alfa-2b and ribavirin resulted in higher incidences of neutropenia and Grade 3-4 neutropenia compared with peginterferon alfa-2b and ribavirin alone (see section 4.8). 
Dodavanje boceprevira peginterferonu alfa-2b i ribavirinu dovelo je do povećane incidencije neutropenije i neutropenije stupnja 3-4, u usporedbi s liječenjem samo peginterferonom alfa-2b i ribavirinom (vidjeti dio 4.8).
The distribution of subjects by genders was 69% men and 31% women. 
Raspodjela ispitanika prema spolu bila je 69% muškaraca i 31% žena.
In subjects treated with boceprevir who did not achieve SVR and with post-baseline samples analysed for RAVs, interferon responsiveness was associated with detection of fewer RAVs, with 31% of these subjects having post-baseline RAVs compared to 69% of subjects with < 1-log10 decline in viral load at Treatment Week 4. 
U ispitanika liječenih boceprevirom koji nisu postigli trajan virološki odgovor, a čiji su uzorci, uzeti nakon početka ispitivanja, analizirani na prisutnost RAV-ova, odgovor na interferon povezan je s manjim brojem otkrivenih RAV-ova; RAV-ovi su ustanovljeni u 31% ovih ispitanika, u usporedbi sa 69% ispitanika u kojih je u 4. tjednu liječenja zabilježeno smanjenje virusnog opterećenja od < 1-log10.
There were 77 subjects who received ≥ 5 steps ribavirin dose reduction for the management of anaemia. 
U 77 ispitanika je radi liječenja anemije doza ribavirina snižavana u ≥ 5 koraka.
Dose modifications due to anaemia/haemolytic anaemia occurred twice as often in patients treated with the combination of Victrelis with peginterferon alfa-2b and ribavirin (26%) compared to peginterferon alfa-2b and ribavirin alone (13%). 
Prilagodba doze zbog anemije/hemolitičke anemije bila je potrebna dvostruko češće u bolesnika liječenih kombinacijom lijeka Victrelis s peginterferonom alfa-2b i ribavirinom (26%), u usporedbi s liječenjem samo peginterferonom alfa-2b i ribavirinom (13%).
Use in patients who have previously failed treatment with an HCV protease inhibitor 
Primjena u bolesnika koji nisu odgovorili na prethodnu terapiju nekim inhibitorom HCV proteaze
Available pharmacodynamic/toxicological data in rats have shown effects of boceprevir/metabolites on fertility, which in females have been shown to 
Dostupni farmakodinamički/toksikološki podaci u štakora pokazali su djelovanje boceprevira i njegovih metabolita na plodnost, koje je u ženki bilo reverzibilno (vidjeti dio 5.3).
Maximum daily dose of Victrelis is 2,400 mg. Administration without food could be associated with a net loss of efficacy due to sub-optimal exposure. 
Primjena bez hrane mogla bi rezultirati neto gubitkom djelotvornosti zbog suboptimalne izloženosti.
Goitre, hypothyroidism Hyperthyroidism 
guša, hipotireoza
Victrelis, in combination with peginterferon alfa and ribavirin, is contraindicated when coadministered with medicines that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as orally administered midazolam and triazolam, bepridil, pimozide, lurasidone, lumefantrine, halofantrine, tyrosine kinase inhibitors, simvastatin, lovastatin, quetiapine, alfuzosin, silodosin, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine) (see section 4.3). 
Victrelis u kombinaciji s peginterferonom alfa i ribavirinom kontraindiciran je ako se istodobno primjenjuju lijekovi čiji se klirens velikim dijelom odvija putem CYP3A4/5 i kod kojih su povišene koncentracije u plazmi povezane s ozbiljnim i/ili po život opasnim nuspojavama - kao što su peroralno primijenjeni midazolam i triazolam, bepridil, pimozid, lurasidon, lumefantrin, halofantrin, inhibitori tirozin kinaze, simvastatin, lovastatin, kvetiapin, alfuzozin, silodozin i derivati ergota (dihidroergotamin, ergonovin, ergotamin, metilergonovin) (vidjeti dio 4.3).
Sustained Virologic Response (SVR) in patients receiving similar therapy up to treatment week 36 
Trajan virološki odgovor (SVR) u bolesnika koji su primali sličnu terapiju do 36. tjedna liječenja
Please refer to the Summary of Product Characteristics for peginterferon alfa. 
Molimo pročitajte Sažetak opisa svojstava lijeka za peginterferon alfa.
Angioedema (see section 4.4), drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, Stevens-Johnson syndrome Musculoskeletal and connective tissue disorders Arthralgia, myalgia 
reakcije fotoosjetljivosti, čir na koži, urtikarija (vidjeti angioedem (vidjeti dio 4.4), sindrom osipa izazvanog lijekom uz eozinofiliju i sustavne simptome (DRESS), Stevens-Johnsonov sindrom
The most frequently (> 25% of subjects) detected post-baseline RAVs in these subjects were amino acid substitutions V36M (61%) and R155K (68%) in subjects infected with genotype 1a viruses and T54A (42%), T54S (37%), A156S (26%) and V170A (32%) in subjects infected with genotype 1b 
Najčešći RAV-ovi otkriveni u tih ispitanika nakon početka ispitivanja (otkriveni u > 25% ispitanika) bili su V36M (61%) i R155K (68%) u ispitanika zaraženih virusom genotipa 1a, te T54A (42%), T54S (37%), A156S (26%) i V170A (32%) u ispitanika zaraženih virusom genotipa 1b.
If such reaction occurs, combination therapy should be discontinued and appropriate medical therapy immediately instituted 
Ako se pojave takve reakcije, treba prekinuti kombiniranu terapiju i odmah uvesti odgovarajuće liječenje (vidjeti dijelove 4.3 i 4.8).
• The Physician Educational Materials (PEM) 
• Materijale za edukaciju liječnika • Sažetak opisa svojstva lijeka (cjeloviti)
The distribution of subjects by gender was 60% men and 40% women. 
Raspodjela ispitanika prema spolu bila je 60% muškaraca i 40% žena.
• were a patient who has previously failed treatment with an HCV protease inhibitor 
• ako ste prethodno neuspješno liječeni nekim inhibitorom HCV proteaze
ACTION 
POSTUPAK
Table 3 Adverse reactions in combination with Victrelis with peginterferon alfa-2b and ribavirin reported during clinical trials 
Nuspojave kombinacije lijeka Victrelis s peginterferonom alfa-2b i ribavirinom prijavljene u kliničkim
Dose reduction of Victrelis is not recommended. 
Ne preporučuje se sniženje doze lijeka Victrelis.
In subjects who demonstrated interferon responsiveness by TW 4, treatment with the combination of Victrelis with peginterferon alfa-2b and ribavirin resulted in SVR rates of 79-81%, compared to 51% in subjects treated with standard of care. 
U ispitanika koji su pokazali odgovor na interferon do 4. tjedna, liječenje kombinacijom lijeka Victrelis s peginterferonom-2b i ribavirinom rezultiralo je stopama SVR od 79-81%, u usporedbi s 51% u ispitanika liječenih standardnom terapijom.
≥ 1-log10 decline 
Odgovor na uvodno liječenje (smanjenje smanjenje za < 1-log10
If permanent discontinuation of peginterferon alfa is required, then ribavirin and Victrelis must also be discontinued. 
Ako je nužno trajno obustaviti liječenje peginterferonom alfa, tada se također mora prekinuti primjena ribavirina i lijeka Victrelis.
What Victrelis looks like and contents of the pack The hard capsules have a yellowish-brown cap with the "MSD" logo printed in red ink and an offwhite body with "314" printed in red ink. 
Tvrde kapsule imaju žućkasto-smeđu kapicu s logotipom "MSD" otisnutim crvenom tintom i bjelkasto tijelo s oznakom "314" otisnutom crvenom tintom.
HCV protease monotherapy 
Monoterapija inhibitorom HCV proteaze
In a pooled analysis of subjects who were previously untreated and subjects who have failed previous therapy who received four weeks of peginterferon alfa-2b and ribavirin followed by boceprevir 800 mg three times daily in combination with peginterferon alfa-2b and ribavirin in two Phase III studies, post-baseline RAVs were detected in 15% of all subjects. 
U zbirnoj analizi ispitanika koji prethodno nisu bili liječeni i ispitanika koji nisu odgovorili na prethodnu terapiju, koji su tijekom 4 tjedna primali peginterferon alfa-2b i ribavirin, a zatim boceprevir u dozi od 800 mg triput na dan u kombinaciji s peginterferonom alfa-2b i ribavirinom u dva klinička ispitivanja faze III, aminokiselinske varijante povezane s rezistencijom (RAV, engl. resistance-associated variants) su nakon početka liječenja otkrivene u 15% svih ispitanika.
- if you are a man who is taking ribavirin: do not have sex with a pregnant woman unless you use a condom. 
Nemojte stupati u spolne odnose s trudnicom bez uporabe kondoma.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist because 
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se liječniku ili ljekarniku jer liječenje možda nije djelotvorno.
Neoplasms benign, malignant and unspecified (including cysts and polyps) Thyroid neoplasm (nodules) 
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe) Rijetko:
o Subjects with a detectable HCV-RNA at TW 8 but subsequently undetectable at TW 12 (late responders) were changed in a blinded fashion to placebo at the TW 36 visit and continued treatment with peginterferon alfa-2b + ribavirin for an additional 12 weeks, for a total treatment duration of 48 weeks. 
o Ispitanici s mjerljivom HCV-RNK u 8. tjednu liječenja, ali s nemjerljivom razinom u 12. tjednu (kasni odgovor), su na posjetu u 36. tjednu liječenja zaslijepljeno prebačeni na placebo i nastavili liječenje peginterferonom alfa-2b + ribavirinom još sljedećih 12 tjedana, što čini ukupno 48 tjedana liječenja.
ethinyl estradiol AUC ↓ 24% ethinyl estradiol Cmax ↔ 
etinilestradiol AUC ↓ 24% etinilestradiol Cmax ↔
If permanent discontinuation of ribavirin is required, then peginterferon alfa and Victrelis must also be discontinued. 
Ako je nužno trajno obustaviti liječenje ribavirinom, tada se također mora prekinuti primjena peginterferona alfa i lijeka Victrelis.
As liver function may change during treatment with Victrelis, a close monitoring of International Normalised Ratio (INR) values is recommended in patients treated with vitamin K antagonists. 
Budući da tijekom liječenja lijekom Victrelis može doći do promjene u funkciji jetre, preporučuje se pomno praćenje vrijednosti međunarodnog normaliziranog omjera (engl.
The activity of boceprevir against the HCV genotype 1a replicon was reduced (2- to 6-fold) by the following amino acid substitutions in the NS3 protease domain: V36A/L/M, Q41R, T54A/S, V55A, R155K and V158I. 
Aktivnost boceprevira protiv replikona HCV genotipa 1a bila je smanjena (2 do 6 puta) zbog sljedećih aminokiselinskih supstitucija u domeni NS3 proteaze: V36A/L/M, Q41R, T54A/S, V55A, R155K i V158I.
The activity of boceprevir against the HCV genotype 1b replicon was reduced (2- to 8-fold) by the following amino acid substitutions in the NS3 protease domain: V36A/M, F43S, T54A/G/S, V55A, R155K/G, V158I, V170M and M175L. 
Aktivnost boceprevira protiv replikona HCV genotipa 1b bila je smanjena (2 do 8 puta) zbog sljedećih aminokiselinskih supstitucija u domeni NS3 proteaze: V36A/M, F43S, T54A/G/S, V55A, R155K/G, V158I, V170M i M175L.